دورية أكاديمية
The relationship between Stroma AReactive Invasion Front Areas (SARIFA), Warburg-subtype and survival: results from a large prospective series of colorectal cancer patients.
| العنوان: | The relationship between Stroma AReactive Invasion Front Areas (SARIFA), Warburg-subtype and survival: results from a large prospective series of colorectal cancer patients. |
|---|---|
| المؤلفون: | Offermans K; Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands., Reitsam NG; Pathology, Medical Faculty, University of Augsburg, Augsburg, Germany.; Bavarian Cancer Research Center (BZKF), Augsburg, Germany., Simons CCJM; Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands., Grosser B; Pathology, Medical Faculty, University of Augsburg, Augsburg, Germany.; Bavarian Cancer Research Center (BZKF), Augsburg, Germany., Zimmermann J; Pathology, Medical Faculty, University of Augsburg, Augsburg, Germany., Grabsch HI; Department of Pathology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands. h.grabsch@maastrichtuniversity.nl.; Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom. h.grabsch@maastrichtuniversity.nl., Märkl B; Pathology, Medical Faculty, University of Augsburg, Augsburg, Germany. bruno.maerkl@uka-science.de.; Bavarian Cancer Research Center (BZKF), Augsburg, Germany. bruno.maerkl@uka-science.de., van den Brandt PA; Department of Epidemiology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands. pa.vandenbrandt@maastrichtuniversity.nl.; Department of Epidemiology, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Center+, Maastricht, the Netherlands. pa.vandenbrandt@maastrichtuniversity.nl. |
| المصدر: | Cancer & metabolism [Cancer Metab] 2024 Jul 11; Vol. 12 (1), pp. 21. Date of Electronic Publication: 2024 Jul 11. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101607582 Publication Model: Electronic Cited Medium: Print ISSN: 2049-3002 (Print) Linking ISSN: 20493002 NLM ISO Abbreviation: Cancer Metab Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, 2013- |
| مستخلص: | Background: Stroma AReactive Invasion Front Areas (SARIFA) is a recently identified haematoxylin & eosin (H&E)based histopathologic biomarker in gastrointestinal cancers, including colorectal cancer (CRC), defined as direct contact between tumour cells and adipocytes at the tumour invasion front. The current study aimed at validating the prognostic relevance of SARIFA in a large population-based CRC series as well as at investigating the relationship between SARIFA-status and previously established Warburg-subtypes, both surrogates of the metabolic state of the tumour cells. Methods: SARIFA-status (positive versus negative) was determined on H&E slides of 1,727 CRC specimens. Warburg-subtype (high versus moderate versus low) data was available from our previous study. The associations between SARIFA-status, Warburg-subtype, clinicopathological characteristics and CRC-specific as well as overall survival were investigated. Results: 28.7% (n=496) CRC were SARIFA-positive. SARIFA-positivity was associated with more advanced disease stage, higher pT category, and more frequent lymph node involvement (all p<0.001). SARIFA-positivity was more common in Warburg-high CRC. 44.2% (n=219) of SARIFA-positive CRCs were Warburg-high compared to 22.8% (n=113) being Warburg-low and 33.1% (n=164) being Warburg-moderate (p<0.001). In multivariable-adjusted analysis, patients with SARIFA-positive CRCs had significantly poorer CRC-specific (HR Conclusions: Our current study is the by far largest external validation of SARIFA-positivity as a novel independent negative prognostic H&E-based biomarker in CRC. In addition, our study shows that SARIFA-positivity is associated with the Warburg-high subtype. Further research is warranted to provide a more mechanistic understanding of the underlying tumour biology. Based on our data, we conclude SARIFA-status should be implemented in pathologic routine practice to stratify CRC patients. (© 2024. The Author(s).) |
| References: | Mod Pathol. 2022 Dec;35(12):2002-2010. (PMID: 36202996) Cancer Gene Ther. 2024 Feb;31(2):207-216. (PMID: 37990064) NPJ Digit Med. 2021 Apr 19;4(1):71. (PMID: 33875798) Sci Rep. 2017 Dec 4;7(1):16878. (PMID: 29203879) Cancers (Basel). 2023 Jan 24;15(3):. (PMID: 36765683) Br J Pharmacol. 2016 Mar;173(6):970-9. (PMID: 26750865) J Pathol. 2022 Jan;256(1):71-82. (PMID: 34580877) Gastroenterology Res. 2018 Aug;11(4):264-273. (PMID: 30116425) Ann Oncol. 2017 Aug 01;28(8):1862-1868. (PMID: 28449055) J Pathol. 2010 Aug;221(4):361-2. (PMID: 20593484) J Pathol. 2018 Sep;246 Suppl 1:S1-S46. (PMID: 30188613) J Gen Physiol. 1927 Mar 7;8(6):519-30. (PMID: 19872213) Eur J Surg Oncol. 2022 Oct;48(10):2075-2081. (PMID: 35768312) Antioxid Redox Signal. 2012 Jun 1;16(11):1264-84. (PMID: 21883043) Histopathology. 2020 Jan;76(2):182-188. (PMID: 31433515) Commun Med (Lond). 2023 Apr 24;3(1):59. (PMID: 37095223) Sci Rep. 2024 Feb 26;14(1):4619. (PMID: 38409377) Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759) Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):51-66. (PMID: 29959989) Cancer Cell. 2015 Jul 13;28(1):42-56. (PMID: 26120082) J Clin Epidemiol. 1990;43(3):285-95. (PMID: 2313318) Int J Epidemiol. 1990 Sep;19(3):553-8. (PMID: 2262247) Oncogenesis. 2022 Aug 9;11(1):46. (PMID: 35945203) J Clin Oncol. 2008 Jan 10;26(2):303-12. (PMID: 18182672) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Cancers (Basel). 2023 Feb 03;15(3):. (PMID: 36765951) Nat Med. 2023 Feb;29(2):430-439. (PMID: 36624314) Nat Metab. 2021 Jan;3(1):21-32. (PMID: 33398194) Drug Resist Updat. 2018 May;38:1-11. (PMID: 29857814) J Hematol Oncol. 2022 Nov 1;15(1):160. (PMID: 36319992) Cancer Lett. 2022 May 28;534:215616. (PMID: 35248624) Nat Commun. 2017 May 31;8:15107. (PMID: 28561063) Trends Cancer. 2020 Jul;6(7):593-604. (PMID: 32610069) J Pathol. 2022 Mar;256(3):269-281. (PMID: 34738636) J Pathol Clin Res. 2022 Mar;8(2):169-180. (PMID: 34791830) Cancer Metastasis Rev. 2022 Sep;41(3):575-587. (PMID: 35941408) Cancer Cell. 2023 Mar 13;41(3):421-433. (PMID: 36801000) Nat Rev Cancer. 2013 Apr;13(4):227-32. (PMID: 23446547) Am Soc Clin Oncol Educ Book. 2018 May 23;38:231-238. (PMID: 30231342) Cancer Res Commun. 2023 Jun 15;3(6):1057-1066. (PMID: 37377615) Nat Commun. 2019 Aug 21;10(1):3763. (PMID: 31434891) Cancers (Basel). 2021 Sep 29;13(19):. (PMID: 34638364) Br J Cancer. 2021 Feb;124(3):634-644. (PMID: 33071283) Transl Oncol. 2024 Jun;44:101913. (PMID: 38593584) Oncotarget. 2016 Oct 4;7(40):64854-64877. (PMID: 27588494) JAMA Oncol. 2017 Feb 01;3(2):194-201. (PMID: 27722750) Cancer Lett. 2020 Aug 1;484:65-71. (PMID: 32387442) |
| فهرسة مساهمة: | Keywords: Biomarker; Colorectal cancer; Histopathology; Invasion front; Rectal cancer; Tumour metabolism; Tumour microenvironment |
| تواريخ الأحداث: | Date Created: 20240711 Latest Revision: 20240714 |
| رمز التحديث: | 20240714 |
| مُعرف محوري في PubMed: | PMC11241902 |
| DOI: | 10.1186/s40170-024-00349-z |
| PMID: | 38992781 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2049-3002 |
|---|---|
| DOI: | 10.1186/s40170-024-00349-z |